Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Net Cash Flow: 2015-2025

Historic Net Cash Flow for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $2.3 million.

  • Seres Therapeutics' Net Cash Flow rose 151.25% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.4 million, marking a year-over-year increase of 79.89%. This contributed to the annual value of -$96.7 million for FY2024, which is 175.72% down from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' Net Cash Flow is $2.3 million, which was up 116.77% from -$13.5 million recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Net Cash Flow ranged from a high of $153.5 million in Q3 2021 and a low of -$68.2 million during Q1 2023.
  • Its 3-year average for Net Cash Flow is -$10.4 million, with a median of -$16.5 million in 2024.
  • In the last 5 years, Seres Therapeutics' Net Cash Flow slumped by 455.46% in 2022 and then spiked by 610.76% in 2023.
  • Seres Therapeutics' Net Cash Flow (Quarterly) stood at -$39.5 million in 2021, then fell by 7.38% to -$42.4 million in 2022, then grew by 1.00% to -$41.9 million in 2023, then climbed by 11.23% to -$37.2 million in 2024, then surged by 151.25% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, -$13.5 million for Q2 2025, and $28.1 million during Q1 2025.